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Current guidelines for COPD recommend a stepwise approach to inhaled pharmacotherapy.1 The 
assessment of COPD is based on severity of airflow limitation (spirometric grades 1-4) as well as 
symptom burden and exacerbation risk (groups A-D). Symptoms and exacerbations are the main 
drivers of treatment. The greatest health care burden is associated with frequent exacerbations of 
COPD – i.e. those patients in groups C and D. 
The guidelines are rather complicated suggesting moving up the treatment escalator from 
monotherapy with long acting beta-agonist (LABA) or long acting muscarinic antagonist 
(LAMA) to combination inhaler therapy with LABA/LAMA or inhaled corticosteroid (ICS) 
with LABA (ICS/LABA) and then triple therapy with ICS/LABA/LAMA. Currently, triple 
therapy requires the use of two separate inhalers comprising ICS/LABA and LAMA often via 
different devices, which in turn may be associated with poorer long term compliance. However 
single triple therapy inhalers currently in development may soon become available including 
once daily with fluticasone furoate/vilanterol/umeclidinium, or twice daily with 
beclometasone/formoterol/glycopyrronium or budesonide/formoterol/glycopyrronium. Given 
that there are already numerous different inhaler devices for mono and dual therapy, prescribers 
are understandably becoming increasingly confused especially in primary care. 
We therefore propose a less complex and more pragmatic approach to prescribing stratified 
by exacerbations and eosinophils, whereby there are only two options for patients with 
COPD, namely single inhalers comprising either LABA/LAMA or ICS/LABA/LAMA 
(Figure). The rationale for this simplified approach is proposed as follows. Using two long 
acting bronchodilators is more effective than one in terms of lung function, symptoms and 
exacerbations.2 Hence it would appear cogent to use a LABA/LAMA single inhaler 
combination as the starting point for patients with increased symptoms or more frequent 
exacerbations. This is also supported by evidence from real life prescribing data where 
patients often step up from monotherapy to combination therapy, presumably because the 
latter results in better control.3 Hence initiating treatment with LABA/LAMA will result in 
fewer treatment failures than monotherapy, in turn improving the likelihood of patients 
adhering to their prescribed inhalers along with a lower health care burden.  
The use of ICS/LABA has been shown to be more effective in reducing exacerbations in 
patients with an eosinophilic component to their COPD.4,5 Moreover patients with COPD 
who have frequent exacerbations in conjunction with blood eosinophilia (>300 cells/ul) are 
at higher risk of exacerbating when stepping down from triple therapy upon subsequent 
withdrawal of ICS.6 7 
The situation with regards to ICS/LABA is further complicated by the results of the FLAME 
study8 which found overall that once daily indacaterol/glycopyrronium was superior to twice 
daily fluticasone/salmeterol for effects on exacerbations, lung function and quality of life. 
However in a subsequent post hoc analysis of FLAME it was found that .LABA/LAMA was 
no better than ICS/LABA on exacerbations in patients with blood eosinophils >300 cells/ul.9 
Triple therapy via a single or separate inhalers containing ICS/LABA/LAMA has been 
shown to be superior to ICS/LABA on lung function, quality of life and exacerbations.10-12 
Given the greater benefits of ICS on exacerbations in patients with eosinophilic COPD, there 
would appear to be a rationale for starting off with triple therapy for individuals with a 
higher exacerbation risk, without going through the first step of ICS/LABA, especially once 
the single triple inhalers become available. Pointedly there are at present no head to head 
comparisons of triple therapy verses LABA/LAMA. However one might expect that triple 
therapy would be superior to LABA/LAMA but only for effects on exacerbations in patients 
with eosinophilic COPD with frequent exacerbations. Whether triple therapy should also be 
considered as step up for non-eosinophilic patients who are exacerbating despite 
LABA/LAMA remains unclear, especially in view of the pneumonia risk associated with 
ICS use.   
Where does this all leave us moving forwards with regards to simplifying inhaled therapy for 
COPD especially for those patients in groups C and D with frequent exacerbations? We 
would suggest a pragmatic approach using single inhaler therapy whereby patients with 
eosinophilic COPD (i.e. >300 cells/ul) receive ICS/LABA/LABA and those with non-
eosinophilic COPD (i.e. <300 cells/ul) receive LABA/LAMA (Figure). For patients in group 
B the starting point irrespective of eosinophils would be LABA/LAMA since these patients 
have more symptoms but infrequent exacerbations and therefore do not need the ICS moiety. 
We would advocate two blood draws if necessary to identify those patients with eosinophilic 
COPD. The most suitable inhaler device for an individual patient is the one which they feel 
comfortable with, can use correctly and will take on a regular basis in the long term. Real life 
studies are now indicated to test this hypothesis in COPD patients stratified according to 
exacerbation frequency and blood eosinophils. Such pragmatic studies should also assess 
whether using a once or twice daily dosing single inhaler regimen is the best way forward. 
 
 
 
  
Figure Legend  
Pragmatic approach to using dual (LABA/LAMA) or triple (ICS/LABA/LAMA) single 
inhaler therapy for COPD stratified according to blood eosinophils (low <300 cells/ul or high 
>300 cells/ul)   and exacerbation risk. The interrupted line between dual and triple therapy 
indicates the possibility of stepping up or down. 
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